tiprankstipranks
Trending News
More News >
FOXO Technologies (FOXO)
:FOXO
US Market

FOXO Technologies (FOXO) AI Stock Analysis

Compare
282 Followers

Top Page

FO

FOXO Technologies

(NYSE MKT:FOXO)

22Underperform
FOXO Technologies receives a low overall stock score primarily due to significant financial challenges, including continuous net losses, high debt, and negative cash flows. The technical analysis also suggests bearish momentum. Although valuation metrics are poor, recent corporate actions, such as acquisitions and restructuring, provide some hope for future improvement. However, these are not sufficient to outweigh the current financial and operational challenges facing the company.

FOXO Technologies (FOXO) vs. S&P 500 (SPY)

FOXO Technologies Business Overview & Revenue Model

Company DescriptionFOXO Technologies (FOXO) is a biotechnology company focused on the application of epigenetic science and AI-driven biomarker discovery for the development of innovative commercial solutions in health and wellness sectors. The company's primary offerings include advanced epigenetic testing services and the development of consumer-oriented products aimed at extending healthspan and promoting longevity. By leveraging cutting-edge scientific research and proprietary technologies, FOXO seeks to address the growing demand for personalized health insights and interventions.
How the Company Makes MoneyFOXO Technologies generates revenue through a combination of direct-to-consumer sales and B2B partnerships. The company offers epigenetic testing services directly to consumers, allowing individuals to gain insights into their biological age and wellness indicators. Additionally, FOXO collaborates with health and wellness companies to integrate its biomarker technologies into their products and services, creating licensing and partnership opportunities. These collaborations enable FOXO to access new markets and expand its revenue streams. The company's revenue model is supported by ongoing advancements in epigenetic science and a growing consumer interest in personalized health solutions.

FOXO Technologies Financial Statement Overview

Summary
FOXO Technologies shows revenue growth but remains unprofitable, with negative net income and high operational costs. The balance sheet reveals financial instability, evidenced by negative equity and reliance on external financing. Cash flow statements indicate heavy dependence on financing activities, posing a risk if such funding becomes unavailable.
Income Statement
30
Negative
FOXO Technologies has shown some revenue growth from 2020 to TTM 2024, yet the company remains unprofitable with consistently negative net income and EBIT margins. The gross profit margin is positive, but high operational costs continue to drive significant net losses. Net profit margin remains deeply negative, indicating challenges in cost management and profitability.
Balance Sheet
20
Very Negative
The balance sheet reflects financial instability, with negative stockholders' equity in recent periods, indicating more liabilities than assets. The debt-to-equity ratio is not applicable due to negative equity, highlighting potential solvency issues. The equity ratio is negative, suggesting high leverage and potential risk in financial sustainability.
Cash Flow
25
Negative
Cash flow statements show negative free cash flow, although there is a slight improvement in operating cash flow in the TTM period. However, the company relies heavily on financing activities for liquidity, which could pose risks if external financing becomes unavailable. Free cash flow to net income and operating cash flow to net income ratios indicate reliance on external funding due to negative net income.
Breakdown
Dec 2023Dec 2022Dec 2021Dec 2020
Income StatementTotal Revenue
145.00K511.00K120.00K63.00K
Gross Profit
13.00K167.00K120.00K63.00K
EBIT
-22.19M-30.08M-15.03M-8.73M
EBITDA
-24.25M-92.09M-37.04M-7.66M
Net Income Common Stockholders
-26.45M-148.90M-40.01M-8.59M
Balance SheetCash, Cash Equivalents and Short-Term Investments
38.00K5.51M6.86M8.12M
Total Assets
725.00K35.41M30.30M9.42M
Total Debt
4.20M3.14M32.20M0.00
Net Debt
4.17M-2.38M25.35M-8.12M
Total Liabilities
14.82M28.70M55.52M704.00K
Stockholders Equity
-14.10M6.71M-25.22M8.72M
Cash FlowFree Cash Flow
-6.64M-25.63M-15.30M-7.06M
Operating Cash Flow
-6.64M-23.76M-15.05M-7.04M
Investing Cash Flow
0.00-1.87M-355.00K-420.00K
Financing Cash Flow
1.17M24.29M14.14M14.14M

FOXO Technologies Technical Analysis

Technical Analysis Sentiment
Negative
Last Price0.72
Price Trends
50DMA
1.36
Negative
100DMA
2.14
Negative
200DMA
2.38
Negative
Market Momentum
MACD
-0.17
Negative
RSI
30.82
Neutral
STOCH
35.42
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FOXO, the sentiment is Negative. The current price of 0.72 is below the 20-day moving average (MA) of 1.02, below the 50-day MA of 1.36, and below the 200-day MA of 2.38, indicating a bearish trend. The MACD of -0.17 indicates Negative momentum. The RSI at 30.82 is Neutral, neither overbought nor oversold. The STOCH value of 35.42 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FOXO.

FOXO Technologies Risk Analysis

FOXO Technologies disclosed 52 risk factors in its most recent earnings report. FOXO Technologies reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

FOXO Technologies Peers Comparison

Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
52
Neutral
$5.36B3.88-42.93%2.87%17.85%1.45%
43
Neutral
$13.08M-55.77%-22.49%54.21%
37
Underperform
$4.21M-1718.32%42.66%-98.89%
27
Underperform
$9.44M-292.41%-64.77%43.53%
22
Underperform
$2.80M-467.31%1397.08%89.53%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
FOXO
FOXO Technologies
0.72
-2.04
-73.91%
STRM
Streamline Health Solutions
3.06
-1.89
-38.18%
ICCT
iCoreConnect
2.03
-20.97
-91.17%
HCTI
Healthcare Triangle
0.21
-1.07
-83.59%

FOXO Technologies Corporate Events

Stock SplitBusiness Operations and Strategy
FOXO Technologies Completes Reverse Stock Split
Neutral
Apr 29, 2025

On April 28, 2025, FOXO Technologies Inc. completed a 1 for 10 reverse stock split, effectively reducing its outstanding common stock from approximately 38.7 million shares to about 3.87 million shares. This strategic move, approved by the company’s directors and shareholders, aims to consolidate shares and adjust stock options and warrants, potentially impacting the company’s market positioning and shareholder value.

Spark’s Take on FOXO Stock

According to Spark, TipRanks’ AI Analyst, FOXO is a Underperform.

FOXO Technologies receives a low overall stock score primarily due to significant financial challenges, including continuous net losses, high debt, and negative cash flows. The technical analysis also suggests bearish momentum. Although valuation metrics are poor, recent corporate actions, such as acquisitions and restructuring, provide some hope for future improvement. However, these are not sufficient to outweigh the current financial and operational challenges facing the company.

To see Spark’s full report on FOXO stock, click here.

Delistings and Listing ChangesStock Split
FOXO Technologies Announces Reverse Stock Split
Neutral
Apr 17, 2025

On April 17, 2025, FOXO Technologies Inc. announced a 1 for 10 reverse stock split of its Class A common stock, effective April 28, 2025. This move, approved by shareholders in November 2024, aims to comply with NYSE American’s listing requirements and is not expected to impact the company’s operations. The reverse split will adjust stock options, warrants, and equity incentive plans proportionately, ensuring uniform effects across all shareholders.

Spark’s Take on FOXO Stock

According to Spark, TipRanks’ AI Analyst, FOXO is a Underperform.

FOXO Technologies faces significant financial challenges, including ongoing losses and high leverage, which weigh heavily on its overall stock score. Technical analysis suggests bearish trends, while valuation metrics highlight profitability issues. However, recent corporate actions offer some optimism for future stability and growth.

To see Spark’s full report on FOXO stock, click here.

M&A TransactionsFinancial DisclosuresRegulatory Filings and Compliance
FOXO Technologies Files Annual Report with Concerns
Negative
Apr 17, 2025

On April 16, 2025, FOXO Technologies Inc. announced the filing of its Annual Report on Form 10-K for the year ending December 31, 2024. The report includes an audit opinion highlighting concerns about the company’s ability to continue as a going concern. Despite these challenges, FOXO completed acquisitions of Myrtle Recovery Centers, Inc. and Rennova Community Health, Inc. in 2024, positioning itself for growth in 2025.

Spark’s Take on FOXO Stock

According to Spark, TipRanks’ AI Analyst, FOXO is a Underperform.

FOXO Technologies faces significant financial challenges, including ongoing losses and high leverage, which weigh heavily on its overall stock score. Technical analysis suggests bearish trends, while valuation metrics highlight profitability issues. However, recent corporate actions offer some optimism for future stability and growth.

To see Spark’s full report on FOXO stock, click here.

M&A TransactionsBusiness Operations and Strategy
FOXO Technologies Announces Acquisition of Vector Biosource
Positive
Mar 19, 2025

On March 19, 2025, FOXO Technologies Inc. announced a non-binding agreement to acquire Vector Biosource Inc., a provider of information and biospecimen sourcing for the biotechnology, clinical research, and pharmaceutical industries. The acquisition is expected to enhance FOXO’s strategic positioning by expanding its platform and providing growth capital and corporate infrastructure to Vector, potentially increasing revenues and synergies with other FOXO subsidiaries.

Business Operations and Strategy
FOXO Technologies’ Subsidiary Achieves Stable Occupancy Rates
Positive
Mar 12, 2025

On March 12, 2025, FOXO Technologies announced that its subsidiary, Myrtle Recovery Centers, Inc., has stabilized its Oneida, Tennessee facility with a consistent occupancy rate of 75% or higher since early 2025 and has finalized contracts with major managed care organizations. Additionally, Myrtle will participate as a Silver Sponsor in the ETAADAC Conference in Knoxville, Tennessee, from March 19-21, 2025, which will gather industry leaders to discuss addiction counseling and treatment advancements.

M&A TransactionsBusiness Operations and Strategy
FOXO Technologies Announces Acquisition of Florida Facilities
Positive
Feb 24, 2025

On February 24, 2025, FOXO Technologies Inc. announced a non-binding acquisition agreement for two assisted living facilities in Florida, valued at $60 million. The acquisition is expected to diversify FOXO’s healthcare offerings and create significant value for shareholders, with completion anticipated within 120 days, subject to due diligence and financing conditions.

Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.